Article
Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study.
BMC cancer - 11 Apr 2023
Hu Xingsheng, Cui Xinge, Wang Ziping, Liu Yunpeng, Luo Ying, Zhong Wei, Zhao Hui, Yao Mengxing, Jiang Da, Wang Mingxia, Chen Minjiang, Zheng Xin, Ding Lieming, Wang Yang, Yuan Xiaobin, Wu Pengxiang, Hu Bei, Han Xiaohong, Shi Yuankai
Abstract excerpt
BACKGROUND: As a potential target receptor tyrosine kinase, mesenchymal-epithelial transition factor (MET) exhibits high aberrant expression across various tumors. This study aimed to evaluated the safety, tolerability, efficacy and pharmacokinetics (PK) of BPI-9016M, a novel tyrosine kinase inhibitor (TKI) targeting c-MET, in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.